LAK细胞和IL－2联合化疗治疗晚期肺癌的近期疗效观察

ＬＡＫ细胞和ＩＬ－２是目前常用的肿瘤生物制剂。自１９９２年以来，对１８例晚期肺癌，男１５例，女３例，年龄２９～６４岁，进行ＬＡＫ细胞和重组ＩＬ－２联合化疗治疗。选择胎脾、胸腺的淋巴细胞做前体细胞，体外用重组ＩＬ－２诱导制备ＬＡＫ细胞，每输３次ＬＡＫ细胞为一疗程、每次输入细胞数０．５～１．０×１０９。化疗采用环磷酰胺，长春新碱，阿霉素为主的方案。治疗结果：完全缓解（ＣＲ）５例，部分缓解（ＰＲ）７例，无效（ＮＲ）３例，病情平稳３例，有效率ＣＲ＋ＰＲ达６６％。采用本疗法后病人精神及饮食好转，能有效缓解胸痛、减轻病人痛苦。提示ＬＡＫ细胞和重组ＩＬ－２联合化疗对晚期肺癌是一种可行的有效治疗，但在临床应用中要注意毒性反应。

Shorty Term Effect of Chemo-therapy Combining LAK Cells and IL-2 in the Treatment of Advanced Lung Cancer

LAK Cells and IL-2 are often used in the treatment of carcinomas. Since 1992, 18 cases of advanced carcinoma of the lung (15 men and 3 woman, aged 29-64 years.) were treated by conmbination of the LAK cells and recombination IL-2 (rIL-2) with chemo-therapy. Lymphocytes from fetal spleen and thymus were isolated in vitro to prepare the LAK cells under the induction of rIL-2. Each cycle of treatment was proceeded by 3 infusions of 0. 15-1. 0X109 LAK cells. The chemo-therapy consisted principally of cyclophosphamide, vincristin and adriamycin. The result of treatment was as follows: complete response in 7 occurred in 5 cases, partial response in 7, no response in 3, stable in 3. The effective rate was 66%. In 4 patients appetite was improved along with relief of pectoralgia. It is suggested that the combination of the LAK cells and rIL-2 with chemotherapy is an effective treatment for lung cancer.